Larimar Therapeutics, Inc.
LRMR
$2.97
$0.113.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.31% | 22.79% | 22.14% | 25.31% | 22.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.15% | 117.66% | 93.92% | 81.82% | 44.16% |
| Operating Income | -107.15% | -117.66% | -93.92% | -81.82% | -44.16% |
| Income Before Tax | -111.26% | -118.15% | -94.04% | -78.75% | -36.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -111.26% | -118.15% | -94.04% | -78.75% | -36.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.26% | -118.15% | -94.04% | -78.75% | -36.85% |
| EBIT | -107.15% | -117.66% | -93.92% | -81.82% | -44.16% |
| EBITDA | -107.78% | -118.52% | -94.65% | -82.48% | -44.56% |
| EPS Basic | -54.29% | -55.30% | -51.40% | -20.11% | 20.14% |
| Normalized Basic EPS | -54.30% | -55.32% | -51.45% | -20.13% | 20.13% |
| EPS Diluted | -54.29% | -55.30% | -51.40% | -20.11% | 20.14% |
| Normalized Diluted EPS | -54.30% | -55.32% | -51.45% | -20.13% | 20.13% |
| Average Basic Shares Outstanding | 37.85% | 39.50% | 28.17% | 33.29% | 44.33% |
| Average Diluted Shares Outstanding | 37.85% | 39.50% | 28.17% | 33.29% | 44.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |